Type of Study:

Observational

Study Design:

Time Perspective: Prospective

Outcome Measure:

The number of adverse events in Japanese subjects treated with nelarabine based on prescribing information under the conditions of general clinical practice.

Outcome Time Frame:

1 year

Safety Issue:

Yes

Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:

GlaxoSmithKline

Authority:

Japan: Pharmaceuticals and Medical Devices Agency

Study ID:

112279

NCT ID:

NCT01376115

Start Date:

January 2008

Completion Date:

January 2018

Related Keywords:

• Cancer